Formas farmacêuticas orais de liberação modificada : análise de siglas e custo-benefício

Abstract

The modified release concept is a general term to describe formulations release features not offered by those of immediate or conventional release. The pharmaceutical industry has a great interest in the modified release medicines, using them as a way to prolong patents. In view of the growing presence of pharmaceutical forms of modified release in the market, it is crucial to know its advantages, disadvantages and acronyms used by manufacturers as well as the total cost of these technologies bring to consumers. Thus the objective of this work is to relate the modified release drugs present in a community pharmacy, with a focus on used acronyms and the cost to the patient. It was a descriptive observational study conducted from data collected in a community pharmacy located in Parquelândia neighborhood in Fortaleza, Ceará, in the period from July to October 2015 and was based on the collection of data on solid oral dosage forms with modified release. It was observed that there is no way of standardization regarding the use of acronyms. Regarding the cost benefit, the drugs that had a lower treatment cost compared with their versions of conventional release are: Anafranil SR® (-14,78%), Dimorf LC® (-46,27%), Donaren RETARD® (-20,31%), Frontal XR® (- 34,46%), Glifage XR® (-61,42%), Melleril RETARD® (-8,02%), Mesacol MMX® (- 13,83%) e Profenid RETARD® (-16,93%). Apresentaram custo de tratamento maior: Cardizem SR® (+16,86%), Dilacoron RETARD® (+26,90%), Monocordil RETARD® (+15,63%) , Natrilix SR® (+3,71%), Balcor SR® (+31,96%), Carbolitium CR® (+39,52% )and Ritalina LA® (+239,98%). Thus, it was concluded that there is need for standardization of acronyms, as well as greater clarity on the part of industry with regard to its use. The cost study showed that in some cases, the modified release medicament provides economic advantage and dosage. In other cases, the cost of treatment was higher, but the advantages of dosage become an attractive to the patient, who will have the option to choose what is most convenient.